Scholar Rock's apitegromab BLA for spinal muscular atrophy was returned in September 2025 with a CMC-only Complete Response Letter tied to Catalent's Bloomington fill-finish facility. On the Q1 2026 earnings call (May 7), management disclosed the BLA has been resubmitted, accepted by FDA with a PDUFA action date of September 30, 2026, and now runs on two independent fill-finish facilities. The market is pricing the path to approval as a single binary on Catalent's classification outcome. The filing argues it isn't.

What the call said

The BLA was resubmitted in late March 2026 "in complete alignment" with FDA following a Type C meeting in early March. Class II resubmission, PDUFA September 30. Two fill-finish facilities are filed in the BLA itself — Catalent Indiana plus a second US-based facility. FDA completed an unannounced re-inspection of Catalent Indiana in early Q2 2026 and now has up to 90 days to classify the facility, putting a decision approximately early-to-mid August 2026. The second facility is independent: "the apitegromab drug product required for FDA data review and potential approval has been filed, and we expect to have ample commercial apitegromab from the facility in early Q3 ahead of the September PDUFA date" (Vaishnaw).

The label was complete pre-CRL. Vaishnaw in Q&A to Michael Yee: "When we got the CRL, the draft label was completed. The one outstanding issue was the manufacturing issue." Label negotiation for children and adults with SMA has not been reopened in any FDA interaction since September 2025.

Cash at Q1 end: $480M (vs. $367.6M Dec 31, 2025) after $100M Blue Owl DDTL-1 drawdown and $98M ATM. Post-approval, an additional $150M DDTL-2 plus a planned PRV monetization (SMA PRVs have historically traded ≈$100M) add roughly $250M more — runway through commercialization. Cash opex run rate is ≈$84M/quarter.

EMA: oral explanation meeting was canceled because written alignment was reached. CHMP opinion expected mid-year 2026. Roche/Chugai dropped their FSHD anti-myostatin antibody program; combined with the prior Biohaven taldefgrobep Phase 3 failure, SRRK is the only Phase 3-positive myostatin inhibitor in SMA and the FORGE Phase 2 FSHD trial enters a cleared competitive field.

What the market thinks

Analyst consensus 18 buy / 0 hold / 0 sell, mean target $59. Short interest compressed from 25.7% pre-call to 15.7% post-call. Jan 2027 ATM straddle implies ±49% move ($23-67 range). Near-dated IV around 71%. Back-solving from current price using bull/base/bear anchors of approximately $75 / $42 / $25 yields a market-implied P(approval) in the 50-55% range.

Our factor scenario assigns 72% to approval-on-time, 20% to delayed (IRL or 3-month extension), 8% to a second CRL. The arithmetic: P(Catalent VAI/NAI = 0.65) × P(approval | good = 0.90) + P(Catalent OAI = 0.35) × P(approval | second facility carries = 0.50) = 0.76. The gap to market: 17-22 percentage points on a $1-2B+ peak sales asset.

Why the gap exists

Three reasons. First, the market is binary-pricing Catalent's August classification when the second facility was filed in the BLA itself — not as a separate sBLA. Cross-ticker work confirms this isn't a sectoral signal: RCKT KRESLADI (approved March 27) uses Rocket's own Cranbury facility; RARE UX-111 uses Ultragenyx's own Bedford facility; only REGN's Eylea HD PFS shares the Catalent Indiana exposure, and REGN already de-risked via an alternate manufacturer. SRRK is the single-name pure-play on a path the market models as binary but the filing structures as parallel.

Second, sell-side has not synthesized the two-step catalyst calendar. The August Catalent classification is a cheap de-risking step six to eight weeks before PDUFA — VAI/NAI compresses approval probability from 76% to roughly 85%; OAI sends pricing back through the second-facility lens. Either way, information arrives with time to act before September 30.

Third, the Germany-first AMNOG strategy management invoked as MFN mitigation is genuinely structural, not spin. The free-pricing window (≈12 months post-EMA approval) means SRRK is unlikely to trip the MFN clause during initial launch. Cross-ticker corroboration: QURE, PTCT, KRYS are executing the same playbook in rare disease. INSM and MDGL pause EU launches because their competitive categories don't sustain above-US prices in the AMNOG window. SRRK's structural position matters; the MFN headwind that's depressing the rare-disease cohort doesn't bind here.

Risks

1. Coordinated C-suite selling on April 16, 2026. Hallal (CEO), Sinha (CFO), Woods (COO) all sold at approximately $50 post-BLA acceptance. Zero open-market P-code purchases anywhere on the Form 4 record. Consistent with routine post-news risk management on concentrated equity, but the absence of any offsetting buying is the largest single caveat on conviction.

2. Catalent Indiana stays OAI. Warning Letter facility with chronic quality issues since June 2022. If classification doesn't clear, approval depends entirely on the second facility, and FDA may need additional review time. Probability roughly 35%.

3. Information Request Letter on second facility data. Class II resubmissions can be extended by 3 months. RARE UX111 precedent: FDA can request additional CMC documentation post-resubmission. Probability 15-20%.

4. Narrower label than expected. Management characterizes the draft label as "children and adults with SMA." The actual draft is not public. Type 1 patients were not in the primary efficacy population. This is a valuation risk (market size), not an approval risk.

5. DOGE/FDA disruption. Flagged in the 10-K as a new risk factor. Has not materialized through the Q1 2026 review cycle, but the September PDUFA window is still ahead.

Catalysts (dated)

• Mid-year 2026: CHMP positive opinion on EU MAA (management guidance)
• Early-to-mid August 2026: FDA classification of Catalent Indiana (90-day window from early Q2 reinspection)
• September 30, 2026: PDUFA action date

What would change our mind

Bear updates: Form 483 published from the Catalent Indiana re-inspection; FDA Information Request Letter on second facility; pre-PDUFA equity raise on capitulatory terms; second Form 483 disclosure at the unnamed second fill-finish facility; PDUFA extension notice.

Bull updates: Catalent Indiana classification letter showing VAI or NAI; insider P-code buying between now and August (notable for its current absence); CHMP positive opinion before mid-July; pre-PDUFA labeling discussions disclosed (typical two to three weeks before approval).

Evidence